Quarterly ResultAug 11, 2026, 07:17 AM
Tango Therapeutics Raises $651.4M; H1 Net Loss $(100.9M)
AI Summary
Tango Therapeutics reported a net loss of $(100.9) million for the six months ended June 30, 2026, with no collaboration revenue. The company significantly strengthened its financial position by raising $651.4 million in net proceeds from an underwritten public offering in June 2026. As of June 30, 2026, its cash, cash equivalents, and marketable securities totaled $1.0 billion, providing a liquidity runway for at least the next 12 months.
Key Highlights
- Net proceeds from June 2026 public offering: $651.4 million.
- Cash, cash equivalents, and marketable securities totaled $1.0 billion.
- Net loss for the six months ended June 30, 2026: $(100.9) million.
- Collaboration revenue for H1 2026 was $0.
- Research and development expenses for H1 2026: $70.7 million.
- General and administrative expenses for H1 2026: $37.8 million.
- Net cash used in operating activities for H1 2026: $(83.2) million.
- Liquidity runway expected for at least 12 months.
Price Impact
More from TNGX